The meningococcal B vaccine Bexsero will be added to the NIP from next month for Indigenous infants and people of all ages with specified medical risk factors, the Federal Health Department has announced.

Patients with asplenia, including sickle cell disease or other haemoglobinopathies, as well as those being treated with eculizumab, are among those who will be eligible for the MenB-MC vaccine, with dosage dependent on their age.